Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Arixtra
Fondaparinux is an anticoagulant medication belonging to the class of synthetic pentasaccharides. It selectively inhibits Factor Xa, a key component of the blood coagulation cascade, thereby preventing the formation of blood clots. Unlike heparin, it does not directly inhibit thrombin. Fondaparinux is used to prevent and treat deep vein thrombosis (DVT) and pulmonary embolism (PE), particularly in surgical settings.
For the prevention and treatment of deep vein thrombosis and pulmonary embolism, especially in surgical settings.
Epidural or spinal hematomas may occur when fondaparinux is used in patients receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Monitor patients frequently for signs and symptoms of neurologic impairment.
Outcome:
Increased bleeding risk
Mechanism:
Synergistic anticoagulant effect
Outcome:
Increased bleeding risk
Mechanism:
Additive anticoagulant effect
Outcome:
Minimal interaction
Mechanism:
Different mechanisms of action
Most likely new formulation: extended-release version (Year 2026, 70% confidence)
Based on current usage trends and clinical trial data, there is a low (5%) likelihood of any major regulatory changes in the next 2 years.
Anticoagulant
Synthetic Pentasaccharide